Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Akebia Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 0.90 · gapped above the open, never looked back. High/low 0.97 at 4:00 am ET, 0.90 at 3:45 pm ET.
169 institutional managers report a position in Akebia Therapeutics, Inc. worth $124.0M between them, filed on form 13F for the quarter ending 2026-06-30. 19 of them hold 80% of it, the largest being BlackRock, Inc. at 18.38%.
144 more managers in the register
19 managers hold 80% of the $124.0M institutional base. The other 150 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
via Jacobs Levy Equity Management, Inc, Acadian Asset Management LLC, Qube Research & Technologies Ltd +1 more · 3.93% of AKBA, 3.72% of PLTK
via Jacobs Levy Equity Management, Inc, Acadian Asset Management LLC, Hennion & Walsh Asset Management, Inc. +1 more · 3.93% of AKBA, 4.94% of FLGT
via Jacobs Levy Equity Management, Inc, Nantahala Capital Management, LLC, Qube Research & Technologies Ltd +4 more · 3.93% of AKBA, 3.26% of KROS
via Acadian Asset Management LLC, Jacobs Levy Equity Management, Inc, Nantahala Capital Management, LLC +2 more · 3.68% of AKBA, 4.79% of ALEC
via Acadian Asset Management LLC, Jacobs Levy Equity Management, Inc, Qube Research & Technologies Ltd +1 more · 3.68% of AKBA, 7.61% of EGAN
via Acadian Asset Management LLC, Jacobs Levy Equity Management, Inc, Qube Research & Technologies Ltd +1 more · 3.68% of AKBA, 3.84% of VNDA
Managers holding a meaningful stake in AKBA also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.
AKBA (Akebia Therapeutics, Inc.) has 8 disclosed suppliers and 13 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: CYCN −3.34%, in healthcare.